Fasenra Dosage
Generic name: BENRALIZUMAB 30mg in 1mL
Dosage form: injection, solution
Drug class: Interleukin inhibitors
Medically reviewed by Drugs.com. Last updated on Sep 17, 2024.
Recommended Dosage for Asthma
Adult and Adolescent Patients 12 Years of Age and Older
The recommended dosage of FASENRA is 30 mg (one injection) administered subcutaneously every 4 weeks for the first 3 doses, and then every 8 weeks thereafter.
Pediatric Patients 6 to 11 Years of Age
The recommended dosage of FASENRA for pediatric patients 6 to 11 years of age is based on body weight as provided in Table 1.
Body weight |
Recommended Dosage |
Less than 35 kg |
10 mg (one injection) administered subcutaneously every 4 weeks for the first 3 doses, and then every 8 weeks thereafter. |
35 kg or more |
30 mg (one injection) administered subcutaneously every 4 weeks for the first 3 doses, and then every 8 weeks thereafter. |
Recommended Dosage for EGPA
The recommended dosage of FASENRA is 30 mg (one injection) administered once every 4 weeks by subcutaneous injection.
General Administration Instructions
FASENRA is for subcutaneous use only.
FASENRA is intended for use under the guidance of a healthcare provider. In line with clinical practice, monitoring of patients after administration of biologic agents is recommended.
Administer FASENRA into the thigh or abdomen. The upper arm can also be used if a healthcare provider or caregiver administers the injection. Prior to administration, warm FASENRA by leaving carton at room temperature for about 30 minutes. Visually inspect FASENRA for particulate matter and discoloration prior to administration. FASENRA is clear to opalescent, colorless to slightly yellow, and may contain a few translucent or white to off-white particles. Do not use FASENRA if the liquid is cloudy, discolored, or if it contains large particles or foreign particulate matter.
Prefilled Syringe
The prefilled syringe is for administration by a healthcare provider.
Autoinjector (FASENRA PEN™)
FASENRA PEN is intended for administration by patients/caregivers. Patients/caregivers may inject after proper training in subcutaneous injection technique, and after the healthcare provider determines it is appropriate.
In asthma patients aged 6 to 11 years weighing 35 kg or more, FASENRA PEN should only be administered by a caregiver or healthcare provider.
Instructions for Administration of FASENRA Prefilled Syringe (Healthcare Providers)
- Figure 1 FASENRA Prefilled Syringes
Prefilled Syringe Components
To prepare FASENRA prefilled syringe for subcutaneous administration, carefully read and adhere to these instructions for use. FASENRA is available in a 10 mg and a 30 mg prefilled syringe. Check the labels on the FASENRA carton and prefilled syringe to ensure the correct 10 mg or 30 mg product is being used (Figure 1). Refer to Figure 1 to identify the prefilled syringe components for use in the administration steps.
Do not touch the needle guard activation clips to prevent premature activation of the needle safety guard.
Instructions for Administration of FASENRA PEN
Refer to the FASENRA PEN ‘Instructions for Use’ for more detailed instructions on the preparation and administration of FASENRA PEN. A patient may self-inject or the patient’s caregiver may administer FASENRA PEN subcutaneously after the healthcare provider determines it is appropriate. In patients aged 6 to 11 years weighing 35 kg or more, FASENRA PEN should only be administered by a caregiver or healthcare provider.
Frequently asked questions
- What are monoclonal antibodies?
- Does Fasenra weaken your immune system?
- How long does Fasenra take to work?
- What is Fasenra used for and how does it work?
- What eosinophil count is needed for Fasenra?
- What type of asthma is Fasenra used to treat?
More about Fasenra (benralizumab)
- Check interactions
- Compare alternatives
- Reviews (75)
- Drug images
- Side effects
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.